{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:20:27Z","timestamp":1794846027584,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2022M711719"],"award-info":[{"award-number":["2022M711719"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"2023 WBN Liver Fibrosis Research Foundation","award":["2024029"],"award-info":[{"award-number":["2024029"]}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic hepatitis B (CHB) remains a global health challenge, with liver fibrosis serving as a critical determinant of disease progression. Despite antiviral treatments, liver fibrosis often persists in CHB patients, highlighting the need for additional biomarkers and therapeutic targets. This study investigates the molecular mechanism underlying HBV-induced liver fibrosis, focusing on the role of RUNX2 in regulating integrin beta-like 1 (ITGBL1), a key factor in fibrogenesis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We examined the relationship between RUNX2 and ITGBL1 in both in vitro hepatocyte models and an in vivo HBV mouse model. Using chromatin immunoprecipitation (ChIP), luciferase reporter assays, and Western blotting, we assessed RUNX2 binding to the ITGBL1 promoter and its impact on gene expression. We also evaluated the effects of RUNX2 inhibition using Vitamin D3 and CADD522 on ITGBL1 expression and hepatic stellate cell activation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our findings reveal that RUNX2 directly binds to the ITGBL1 promoter, enhancing its expression and promoting hepatic stellate cell activation. We show that HBV infection significantly upregulates both RUNX2 and ITGBL1 in liver cells. Inhibition of RUNX2 with Vitamin D3 or CADD522 significantly reduced ITGBL1 levels and blocked hepatic stellate cell activation. These results suggest that the RUNX2\/ITGBL1 pathway is critical in the progression of liver fibrosis in HBV-infected patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>RUNX2 promotes liver fibrosis in HBV-infected patients by upregulating ITGBL1 expression. Our findings suggest that targeting RUNX2 could be a potential therapeutic approach to mitigate liver fibrosis in chronic hepatitis B.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12985-025-02749-z","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:37:19Z","timestamp":1745660239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HBV activates hepatic stellate cells through RUNX2\/ITGBL1 axis"],"prefix":"10.1186","volume":"22","author":[{"given":"Fengchun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1405-7131","authenticated-orcid":false,"given":"Yongxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-6425","authenticated-orcid":false,"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-8616","authenticated-orcid":false,"given":"Demin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"2749_CR1","unstructured":"Organization WH. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016\u20132021. World Health Organization; 2019."},{"issue":"10381","key":"2749_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepat B Lancet. 2023;401(10381):1039\u201352.","journal-title":"Hepat B Lancet"},{"issue":"6","key":"2749_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/jiaa266","volume":"225","author":"G Rong","year":"2022","unstructured":"Rong G, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with Entecavir: A multicenter, randomized, Double-Blind, Placebo-Controlled trial. J Infect Dis. 2022;225(6):1091\u20139.","journal-title":"J Infect Dis"},{"issue":"5","key":"2749_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00535-023-01970-3","volume":"58","author":"X Chang","year":"2023","unstructured":"Chang X, et al. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2023;58(5):481\u201393.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2749_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41467-020-14869-x","volume":"11","author":"Q Ji","year":"2020","unstructured":"Ji Q, et al. Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation. Nat Commun. 2020;11(1):1211.","journal-title":"Nat Commun"},{"issue":"13","key":"2749_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.devcel.2023.04.014","volume":"58","author":"J Zhao","year":"2023","unstructured":"Zhao J, et al. Mechanical pressure-induced dedifferentiation of myofibroblasts inhibits scarring via SMYD3\/ITGBL1 signaling. Dev Cell. 2023;58(13):1139\u2013e11526.","journal-title":"Dev Cell"},{"issue":"10","key":"2749_CR7","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/cvr\/cvad104","volume":"119","author":"X Chen","year":"2023","unstructured":"Chen X, et al. Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy. Cardiovasc Res. 2023;119(10):1928\u201341.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2749_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ymthe.2018.08.026","volume":"27","author":"X Song","year":"2019","unstructured":"Song X, et al. LncITPF promotes pulmonary fibrosis by targeting hnRNP-L depending on its host gene ITGBL1. Mol Ther. 2019;27(2):380\u201393.","journal-title":"Mol Ther"},{"key":"2749_CR9","doi-asserted-by":"crossref","unstructured":"Wang M et al. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep, 2017.","DOI":"10.1038\/srep43446"},{"key":"2749_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JHC.S306966","volume":"8","author":"F Ye","year":"2021","unstructured":"Ye F, et al. Serum levels of ITGBL1 as an early diagnostic biomarker for hepatocellular carcinoma with hepatitis B virus infection. J Hepatocell Carcinoma. 2021;8:285\u2013300.","journal-title":"J Hepatocell Carcinoma"},{"issue":"1\u20132","key":"2749_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevEukaryotGeneExpr.v14.i12.10","volume":"14","author":"JB Lian","year":"2004","unstructured":"Lian JB, et al. Regulatory controls for osteoblast growth and differentiation: role of Runx\/Cbfa\/AML factors. Crit Rev Eukaryot Gene Expr. 2004;14(1\u20132):1\u201341.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"6","key":"2749_CR12","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.athoracsur.2020.12.058","volume":"112","author":"XS Deng","year":"2021","unstructured":"Deng XS, et al. Complement upregulates Runx-2 to induce profibrogenic change in aortic valve interstitial cells. Ann Thorac Surg. 2021;112(6):1962\u201372.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"2749_CR13","doi-asserted-by":"publisher","first-page":"e2304408","DOI":"10.1002\/advs.202304408","volume":"11","author":"K Wu","year":"2024","unstructured":"Wu K, et al. Loss of SLC27A5 activates hepatic stellate cells and promotes liver fibrosis via unconjugated cholic acid. Adv Sci (Weinh). 2024;11(2):e2304408.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"2749_CR14","doi-asserted-by":"publisher","first-page":"e1316","DOI":"10.1002\/ctm2.1316","volume":"13","author":"L Zhong","year":"2023","unstructured":"Zhong L, et al. Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression. Clin Transl Med. 2023;13(7):e1316.","journal-title":"Clin Transl Med"},{"key":"2749_CR15","volume-title":"ITGBL1 is a Runx2 transcriptional target and promotes breast Cancer bone metastasis by activating the TGF beta signaling pathway","author":"Dong-Mei","year":"2015","unstructured":"Dong-Mei, et al. ITGBL1 is a Runx2 transcriptional target and promotes breast Cancer bone metastasis by activating the TGF beta signaling pathway. Cancer research: The official organ of the American Association for Cancer Research, Inc; 2015."},{"issue":"1","key":"2749_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-019-0945-y","volume":"18","author":"T Matsuyama","year":"2019","unstructured":"Matsuyama T, et al. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer. Mol Cancer. 2019;18(1):19.","journal-title":"Mol Cancer"},{"issue":"1","key":"2749_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-020-01306-2","volume":"20","author":"Y Cheli","year":"2021","unstructured":"Cheli Y, et al. ITGBL1 is a new Immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer. 2021;20(1):12.","journal-title":"Mol Cancer"},{"issue":"4","key":"2749_CR18","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.77.4.2489-2499.2003","volume":"77","author":"X Yu","year":"2003","unstructured":"Yu X, Mertz JE. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J Virol. 2003;77(4):2489\u201399.","journal-title":"J Virol"},{"issue":"2","key":"2749_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/excr.2002.5474","volume":"274","author":"H Drissi","year":"2002","unstructured":"Drissi H, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2\/Cbfa1 gene promoter. Exp Cell Res. 2002;274(2):323\u201333.","journal-title":"Exp Cell Res"},{"issue":"1","key":"2749_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12951-025-03133-3","volume":"23","author":"Y Gong","year":"2025","unstructured":"Gong Y, et al. Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence. J Nanobiotechnol. 2025;23(1):100.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"2749_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cac2.12464","volume":"43","author":"L He","year":"2023","unstructured":"He L, et al. HMMR alleviates Endoplasmic reticulum stress by promoting autophagolysosomal activity during Endoplasmic reticulum stress-driven hepatocellular carcinoma progression. Cancer Commun (Lond). 2023;43(9):981\u20131002.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"2749_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3350\/cmh.2024.0252","volume":"30","author":"GA Kim","year":"2024","unstructured":"Kim GA, et al. Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B. Clin Mol Hepatol. 2024;30(4):793\u2013806.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"2749_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41418-022-01010-2","volume":"29","author":"X Yin","year":"2022","unstructured":"Yin X, et al. RUNX2 recruits the NuRD(MTA1)\/CRL4B complex to promote breast cancer progression and bone metastasis. Cell Death Differ. 2022;29(11):2203\u201317.","journal-title":"Cell Death Differ"},{"key":"2749_CR24","doi-asserted-by":"crossref","unstructured":"Fang Y et al. RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition. Nature, 2025.","DOI":"10.1038\/s41586-024-08542-2"},{"key":"2749_CR25","doi-asserted-by":"crossref","unstructured":"Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology, 2013. 58.","DOI":"10.1002\/hep.26488"},{"key":"2749_CR26","unstructured":"Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol, 2015. 63(5): pp. 1086\u201392."},{"issue":"4","key":"2749_CR27","first-page":"783","volume":"13","author":"LH Wong","year":"2015","unstructured":"Wong LH, et al. Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. Clinical Gastroenterology & Hepatology the Official Clinical Practice. J Am Gastroenterological Association. 2015;13(4):783\u2013e7901.","journal-title":"J Am Gastroenterological Association"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02749-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:37:23Z","timestamp":1745660243000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02749-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02749-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with local animal welfare regulations and the guidelines for the care and use of laboratory animals. The study received approval from the Animal Ethics Committee of the School of Basic Medical Sciences, Fudan University (Approval No. 20210302-103).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}